GetTopicDetailResponse(id=6d448341139, topicName=胃食管腺癌, introduction=胃食管腺癌, content=null, image=null, comments=2, allHits=2052, url=https://h5.medsci.cn/topic?id=83411, type=0, isShow=1, status=1, isAdmin=null, adminId=1, adminEncryptionId=1eae1, adminName=小M, createdBy=null, createdName=, createdAvatar=, createdTime=Fri May 29 21:19:53 CST 2020, time=2020-05-29, bannerImg=https://img.medsci.cn/202167/1623032167418_5160405.png, bannerImgH5=https://img.medsci.cn/202167/1623032167418_5160405.png, likes=0, followStatus=false, moduleDTOList=null, tagId=84598, tagList=[TagDto(tagId=84598, tagName=胃食管腺癌)], ipAttribution=, topicAdmin=1, lengthMark=0)
[GetTopicListResponse(id=2254238, encodeId=966e225423810, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a> <a href='/topic/show?id=6d448341139' target=_blank style='color:#2F92EE;'>#胃食管腺癌#</a>, objectTitle=腹膜轉(zhuǎn)移的胃食管腺癌，原發(fā)灶與轉(zhuǎn)移灶的PD-L1表達(dá)一致性如何？, objectType=article, longId=865165, objectId=446686516512, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/Random/doctor-using-smartphone-app-in-hospital-office-PEMB8JL.jpg, objectUrl=/article/show_article.do?id=446686516512, replyNumber=0, likeNumber=31, createdTime=2025-03-02, rootId=0, userName=梅斯管理員, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=陜西省, moduleDTOList=[ModuleDTO(moduleId=446686516512, moduleTitle=腹膜轉(zhuǎn)移的胃食管腺癌，原發(fā)灶與轉(zhuǎn)移灶的PD-L1表達(dá)一致性如何？, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=446686516512)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2211254, encodeId=6dfb2211254d3, content=<a href='/topic/show?id=cbef6022e4c' target=_blank style='color:#2F92EE;'>#曲妥珠單抗#</a> <a href='/topic/show?id=6d448341139' target=_blank style='color:#2F92EE;'>#胃食管腺癌#</a>, objectTitle=HER2陽(yáng)性胃食管腺癌患者圍手術(shù)期化療加用曲妥珠單抗安全可行，且延長(zhǎng)無(wú)病生存期, objectType=article, longId=831297, objectId=f5a983129e90, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240622/1719059299735_5579292.jpg, objectUrl=/article/show_article.do?id=f5a983129e90, replyNumber=0, likeNumber=111, createdTime=2024-06-23, rootId=0, userName=梅斯管理員, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=f5a983129e90, moduleTitle=HER2陽(yáng)性胃食管腺癌患者圍手術(shù)期化療加用曲妥珠單抗安全可行，且延長(zhǎng)無(wú)病生存期, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=f5a983129e90)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2111269, encodeId=7d38211126984, content=<a href='/topic/show?id=c95f1051221b' target=_blank style='color:#2F92EE;'>#Jazz#</a> Pharmaceuticals和Zymeworks共同宣布，其聯(lián)合開(kāi)發(fā)的在研<a href='/topic/show?id=2ad83e51258' target=_blank style='color:#2F92EE;'>#雙特異性抗體#</a><a href='/topic/show?id=a29a10512337' target=_blank style='color:#2F92EE;'>#zanidatamab#</a>(<a href='/topic/show?id=3daf10512420' target=_blank style='color:#2F92EE;'>#澤尼達(dá)妥單抗#</a>)與化療組合療法在臨床2期試驗(yàn)當(dāng)中展現(xiàn)積極結(jié)果。分析顯示，接受此組合療法作為一線療法的轉(zhuǎn)移性HER2陽(yáng)性<a href='/topic/show?id=6d448341139' target=_blank style='color:#2F92EE;'>#胃食管腺癌#</a>（mGEA）患者的總生存率達(dá)84%（隨訪18個(gè)月）。此組合療法的關(guān)鍵臨床3期試驗(yàn)正在進(jìn)行中，預(yù)計(jì)于2024年公布結(jié)果。<a href='/topic/show?id=2b1810512568' target=_blank style='color:#2F92EE;'>#HER2靶點(diǎn)#</a>具有通用性，未來(lái)與<a href='/topic/show?id=2f1862e434' target=_blank style='color:#2F92EE;'>#DS-8201#</a>直接競(jìng)爭(zhēng)，到底是HER2的<a href='/topic/show?id=b5f71041887c' target=_blank style='color:#2F92EE;'>#ADC類(lèi)藥物#</a>強(qiáng)，還是雙特異性抗體厲害，會(huì)是接下來(lái)幾年最令人感興趣的話題, objectTitle=zanidatamab(澤尼達(dá)妥單抗)對(duì)轉(zhuǎn)移性HER2陽(yáng)性胃食管腺癌（mGEA）一線治療18個(gè)月總生存率為84%, objectType=article, longId=757112, objectId=28d4e5711264, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/images/20230111/3963305ca6d7449fadacd8d4833b3e30.jpg, objectUrl=/article/show_article.do?id=28d4e5711264, replyNumber=0, likeNumber=149, createdTime=2023-01-24, rootId=0, userName=showtest, userId=8f0715, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=28d4e5711264, moduleTitle=zanidatamab(澤尼達(dá)妥單抗)對(duì)轉(zhuǎn)移性HER2陽(yáng)性胃食管腺癌（mGEA）一線治療18個(gè)月總生存率為84%, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=28d4e5711264)], followStatus=false, userIsMember=false, type=1, lengthMark=1), GetTopicListResponse(id=1247599, encodeId=d40f124e5998b, content=<a href='/topic/show?id=6d448341139' target=_blank style='color:#2F92EE;'>#胃食管腺癌#</a><a href='/topic/show?id=e3818e1893' target=_blank style='color:#2F92EE;'>#HER2#</a><a href='/topic/show?id=2ad83e51258' target=_blank style='color:#2F92EE;'>#雙特異性抗體#</a>，如果這個(gè)抗體將來(lái)再接一個(gè)細(xì)胞毒的，做成<a href='/topic/show?id=6f6c19562f' target=_blank style='color:#2F92EE;'>#ADC#</a>類(lèi)，會(huì)不會(huì)效果更好？？, objectTitle=治療胃食管腺癌達(dá)到90.9%疾病控制率，Zymeworks HER2靶向雙特異性抗體顯“奇效”, objectType=article, longId=259632, objectId=614325963215, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/images/20220901/fd150596f89f4c9aab6627cae756b797.jpg, objectUrl=/article/show_article.do?id=614325963215, replyNumber=0, likeNumber=208, createdTime=2022-09-07, rootId=0, userName=小小醫(yī)者, userId=f63e4754896, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=614325963215, moduleTitle=治療胃食管腺癌達(dá)到90.9%疾病控制率，Zymeworks HER2靶向雙特異性抗體顯“奇效”, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=614325963215)], followStatus=false, userIsMember=false, type=1, lengthMark=0)]
梅斯話題小助手
2020-05-29
